Overview

• US biotech firm's Q1 net revenue fell yr/yr to $34.7 mln

• Acute care franchise revenue grew 32% yr/yr, offset by oncology sales decline

• Company reaffirmed 2026 guidance

Outlook

• Heron reaffirms 2026 full-year net revenue guidance of $173 mln to $183 mln

• Company maintains 2026 adjusted EBITDA guidance of $10 mln to $20 mln

Result Drivers

• ACUTE CARE GROWTH - Revenue from the Acute Care franchise rose 32% yr/yr, driven by higher demand for ZYNRELEF and APONVIE

• ONCOLOGY REVENUE DECLINE - Oncology Supportive Care revenue fell yr/yr, reflecting lower CINVANTI and SUSTOL sales

Company press release: ID:nGNXt6hYB

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Heron Therapeutics Inc is $4.00, about 230.6% above its May 8 closing price of $1.21

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.